Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
91074 trials found · Page 124 of 4554
-
Lower radiation, same punch: new combo aims to tame rare lymphoma
Disease control Not yet recruitingExtranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus-associated non-Hodgkin lymphoma with high incidence in Asia and Latin America. Approximately 70% of patients present with early-stage (I-II) disease confined to the upper aerodigestive tract. Radiotherapy at 50-56 Gy…
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
Could an HIV drug soothe stubborn throat reflux?
Disease control Not yet recruitingLaryngopharyngeal Reflux (LPR) is a common condition that causes symptoms like chronic cough, throat clearing, hoarseness, and trouble swallowing. If not treated, LPR can lead to long-term throat damage and may increase the risk of throat cancer. More than 20% of the people in th…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
Gene therapy trial hopes to tame severe bleeding disorder
Disease control Recruiting nowThis study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
New brain bleed surgery could save lives and reduce disability
Disease control Not yet recruitingMINUTE is a prospective, multi-center, randomized, controlled, blinded assessor, adaptive enrichment design, clinical trial. Eligible patients with spontaneous BGH ≥20 mL will be randomized 1:1 to either minimally invasive endoscopic SCUBA evacuation plus standard medical managem…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated May 07, 2026 12:19 UTC
-
New cocktail targets Hard-to-Treat sarcomas
Disease control Not yet recruitingA multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. …
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
New heart pump could be lifeline for failing hearts
Disease control Not yet recruitingThis clinical investigation evaluates the safety and clinical performance of the BrioVAD Left Ventricular Assist System in patients with advanced, refractory left ventricular heart failure who require mechanical circulatory support.
Phase: NA • Sponsor: BrioHealth BV • Aim: Disease control
Last updated May 05, 2026 11:55 UTC
-
Promising new combo aims to improve leukemia treatment
Disease control ENROLLING_BY_INVITATIONThis phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?"
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 07, 2026 12:18 UTC
-
Magic mushroom therapy offers hope for cancer Patients' mental health
Symptom relief Recruiting nowThis phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) …
Phase: PHASE2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Apr 30, 2026 15:49 UTC
-
New combo therapy aims to shrink enlarged spleens in myelofibrosis patients
Disease control Recruiting nowThe purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essent…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New daily pill aims to prevent TB in kids, including those with HIV
Prevention Not yet recruitingThis study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB). The study will take place at multiple locations and children under 13 years old will be divided into two groups: one group will include c…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Apr 30, 2026 15:52 UTC
-
Can a pill help you quit vaping for good? major trial underway
Disease control Not yet recruitingThis will be a multi-center, double-blind, randomized, placebo-controlled, Phase 3 study conducted in male or female adults who are daily nicotine e-cigarette users only. A total of approximately 800 subjects will be randomly assigned (1:1) to one of two Arms: * Arm B, 12 weeks…
Phase: PHASE3 • Sponsor: Achieve Life Sciences • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC
-
New combo therapy targets rare, aggressive lung cancer
Disease control Recruiting nowThis study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop the…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC
-
RNA vaccine trial offers new hope for kids with recurrent brain cancer
⭐️ VACCINE ⭐️ Recruiting nowThe primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in pediatric patients with recurrent/progressive Medulloblastoma (MB)
Phase: PHASE1 • Sponsor: University of Florida • Aim: ⭐️ VACCINE ⭐️
Last updated May 06, 2026 16:03 UTC
-
New gene therapy aims to help babies with deadly muscle disease
Disease control Not yet recruitingThis is a phase I/II clinical study to evaluate the safety, preliminary efficacy and immunogenicity of SKG0201 injection in subjects with Spinal Muscular Atrophy Type I.
Phase: PHASE1, PHASE2 • Sponsor: Lanyue Biotech (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
New drug targets Hard-to-Treat breast cancer in 36-Patient trial
Disease control Not yet recruitingThis phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are p…
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New combo aims to outsmart Drug-Resistant lung cancer
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Osimertinib plus Capivasertib works to treat EGFRm advanced non-small cell lung cancer (NSCLC) in participants with PIK3CA/AKT1/PTEN alterations after progression on first-line Osimertinib (monotherapy or plus chemotherapy). The mai…
Phase: PHASE1, PHASE2 • Sponsor: Shanxi Province Cancer Hospital • Aim: Disease control
Last updated May 07, 2026 12:18 UTC
-
New cream could speed wound healing for kids with butterfly skin
Disease control Not yet recruitingThe upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry. There are only 4 site visits by patients with minimal assessments over a 2-month period, and pat…
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New drug aims to calm brain inflammation in rare autoimmune disease
Disease control Not yet recruitingThis study will evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics (PK) of ART5803 in adult participants with a confirmed diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (ANRE) or anti-NMDAR autoantibody-associated psychiatric diseas…
Phase: PHASE2 • Sponsor: Arialys Australia Pty Ltd • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
New hope for advanced breast cancer: phase 3 trial compares novel combo to standard care
Disease control Not yet recruitingThe purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone rece…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Engineered immune cells take on deadliest lung cancer
Disease control Not yet recruitingBackground: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that develops anywhere other than the lungs. EPNEC is also deadly. B7-H3 is a protein often found in SCLC and EPNEC tumor cell…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 12:18 UTC